ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR)
CUSIP: 04280A100
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 135,488,140
- Total 13F shares
- 97,822,928
- Share change
- +2,388,864
- Total reported value
- $2,542,052,894
- Put/Call ratio
- 41%
- Price per share
- $25.99
- Number of holders
- 272
- Value change
- +$57,202,679
- Number of buys
- 129
- Number of sells
- 119
Quarterly Holders Quick Answers
What is CUSIP 04280A100?
CUSIP 04280A100 identifies ARWR - ARROWHEAD PHARMACEUTICALS, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 04280A100:
Top shareholders of ARWR - ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock Finance, Inc. |
13F
|
Company |
11%
|
15,346,637
|
$438,913,819 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
9.2%
|
12,404,050
|
$354,755,829 | — | 31 Mar 2024 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
6.3%
|
8,555,555
|
$244,688,873 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
4.8%
|
6,560,703
|
$187,636,106 | — | 31 Mar 2024 | |
| FMR LLC |
13F
|
Company |
4.7%
|
6,394,628
|
$182,886,375 | — | 31 Mar 2024 | |
| Slate Path Capital LP |
13F
|
Company |
3.1%
|
4,139,000
|
$118,375,400 | — | 31 Mar 2024 | |
| Artal Group S.A. |
13F
|
Company |
2.2%
|
3,036,668
|
$86,848,705 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2%
|
2,754,634
|
$78,794,305 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.9%
|
2,638,063
|
$75,448,601 | — | 31 Mar 2024 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
1.3%
|
1,758,883
|
$50,305,000 | — | 31 Mar 2024 | |
| NORGES BANK |
13F
|
Company |
1.2%
|
1,672,859
|
$47,843,767 | — | 31 Mar 2024 | |
| CREDIT SUISSE AG/ |
13F
|
Company |
1.2%
|
1,626,513
|
$46,518,272 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.96%
|
1,300,649
|
$37,198,562 | — | 31 Mar 2024 | |
| Rokos Capital Management LLP |
13F
|
Company |
0.91%
|
1,229,148
|
$35,153,633 | — | 31 Mar 2024 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.9%
|
1,225,987
|
$35,063,228 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.84%
|
1,135,867
|
$32,485,794 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.78%
|
1,054,983
|
$30,172,504 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.77%
|
1,049,539
|
$30,016,815 | — | 31 Mar 2024 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.74%
|
997,297
|
$28,522,679 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.73%
|
983,755
|
$28,135,393 | — | 31 Mar 2024 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.69%
|
933,900
|
$26,709,540 | — | 31 Mar 2024 | |
| Aquilo Capital Management, LLC |
13F
|
Company |
0.67%
|
908,474
|
$25,982,356 | — | 31 Mar 2024 | |
| Western Financial Corp/CA |
13F
|
Company |
0.61%
|
820,239
|
$23,458,835 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.55%
|
741,897
|
$21,218,254 | — | 31 Mar 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.55%
|
739,651
|
$21,154,019 | — | 31 Mar 2024 | |
| E. Ohman J:or Asset Management AB |
13F
|
Company |
0.47%
|
640,160
|
$18,308,576 | — | 31 Mar 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.41%
|
555,628
|
$15,890,961 | — | 31 Mar 2024 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.36%
|
484,120
|
$13,845,832 | — | 31 Mar 2024 | |
| Capital International Investors |
13F
|
Company |
0.35%
|
479,106
|
$13,702,432 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.34%
|
460,770
|
$13,178,023 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.33%
|
450,921
|
$12,896,341 | — | 31 Mar 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.31%
|
415,783
|
$11,891,393 | — | 31 Mar 2024 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.27%
|
372,105
|
$10,642,184 | — | 31 Mar 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.27%
|
359,470
|
$10,280,842 | — | 31 Mar 2024 | |
| Retirement Systems of Alabama |
13F
|
Company |
0.26%
|
348,784
|
$9,975,222 | — | 31 Mar 2024 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.25%
|
344,467
|
$9,851,756 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.24%
|
328,033
|
$9,381,744 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.24%
|
326,971
|
$9,351,371 | — | 31 Mar 2024 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.23%
|
313,289
|
$8,960,065 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.21%
|
280,984
|
$8,036,142 | — | 31 Mar 2024 | |
| Mirae Asset Global Investments Co., Ltd. |
13F
|
Company |
0.24%
|
327,782
|
$8,003,902 | — | 31 Mar 2024 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.2%
|
274,159
|
$7,840,947 | — | 31 Mar 2024 | |
| Legal & General Group Plc |
13F
|
Company |
0.2%
|
274,050
|
$7,837,829 | — | 31 Mar 2024 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.2%
|
273,936
|
$7,834,570 | — | 31 Mar 2024 | |
| Javier San Martin |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
198,497
|
$7,417,833 | — | 04 Jan 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.19%
|
254,240
|
$7,271,264 | — | 31 Mar 2024 | |
| Octagon Capital Advisors LP |
13F
|
Company |
0.18%
|
250,000
|
$7,150,000 | — | 31 Mar 2024 | |
| JOHNSON & JOHNSON |
13F
|
Company |
0.18%
|
247,598
|
$7,081,303 | — | 31 Mar 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.18%
|
243,853
|
$6,974,196 | — | 31 Mar 2024 | |
| Swiss National Bank |
13F
|
Company |
0.18%
|
243,300
|
$6,958,380 | — | 31 Mar 2024 |
Institutional Holders of ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) as of Q2 2024
As of 30 Jun 2024,
ARROWHEAD PHARMACEUTICALS, INC. - Common Stock (ARWR) was held by
272 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
97,822,928 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, Avoro Capital Advisors LLC, FMR LLC, STATE STREET CORP, Slate Path Capital LP, Artal Group S.A., GEODE CAPITAL MANAGEMENT, LLC, T. Rowe Price Investment Management, Inc., and JPMORGAN CHASE & CO.
This page lists
271
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
267
Q2 2024 holders
272
Holder diff
5
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.